A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Cixutumumab (Primary) ; Temsirolimus
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 04 Sep 2015 New trial record